333 related articles for article (PubMed ID: 26386857)
1. Reduced Risk of Barrett's Esophagus in Statin Users: Case-Control Study and Meta-Analysis.
Beales IL; Dearman L; Vardi I; Loke Y
Dig Dis Sci; 2016 Jan; 61(1):238-46. PubMed ID: 26386857
[TBL] [Abstract][Full Text] [Related]
2. Statin use is associated with a decreased risk of Barrett's esophagus.
Nguyen T; Khalaf N; Ramsey D; El-Serag HB
Gastroenterology; 2014 Aug; 147(2):314-23. PubMed ID: 24798416
[TBL] [Abstract][Full Text] [Related]
3. Statin use is associated with a reduction in the incidence of esophageal adenocarcinoma: a case control study.
Beales IL; Vardi I; Dearman L; Broughton T
Dis Esophagus; 2013; 26(8):838-46. PubMed ID: 22989236
[TBL] [Abstract][Full Text] [Related]
4. Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus.
Thrift AP; Anderson LA; Murray LJ; Cook MB; Shaheen NJ; Rubenstein JH; El-Serag HB; Vaughan TL; Schneider JL; Whiteman DC; Corley DA
Am J Gastroenterol; 2016 Nov; 111(11):1528-1535. PubMed ID: 27575711
[TBL] [Abstract][Full Text] [Related]
5. Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma.
Beales IL; Vardi I; Dearman L
Eur J Gastroenterol Hepatol; 2012 Aug; 24(8):917-23. PubMed ID: 22569083
[TBL] [Abstract][Full Text] [Related]
6. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of Barrett's esophagus.
Schneider JL; Zhao WK; Corley DA
Dig Dis Sci; 2015 Feb; 60(2):436-43. PubMed ID: 25213077
[TBL] [Abstract][Full Text] [Related]
7. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.
Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ;
Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200
[TBL] [Abstract][Full Text] [Related]
8. Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis.
Wang F; Lv ZS; Fu YK
Dis Esophagus; 2011 Jul; 24(5):318-24. PubMed ID: 21166737
[TBL] [Abstract][Full Text] [Related]
9. Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett's esophagus: a nested case-control study.
Nguyen T; Duan Z; Naik AD; Kramer JR; El-Serag HB
Gastroenterology; 2015 Nov; 149(6):1392-8. PubMed ID: 26208896
[TBL] [Abstract][Full Text] [Related]
10. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.
Masclee GM; Coloma PM; Spaander MC; Kuipers EJ; Sturkenboom MC
BMJ Open; 2015 Jan; 5(1):e006640. PubMed ID: 25633286
[TBL] [Abstract][Full Text] [Related]
11. Medical Prevention of Barrett's Esophagus: Effects of Statins, Aspirin, Non-aspirin NSAIDs, Calcium, and Multivitamins.
Goldberg A; Gerkin RD; Young M
Dig Dis Sci; 2015 Jul; 60(7):2058-62. PubMed ID: 25680872
[TBL] [Abstract][Full Text] [Related]
12. Systematic Review and Meta-analysis: Use of Statins Is Associated with a Reduced Incidence of Oesophageal Adenocarcinoma.
Thomas T; Loke Y; Beales ILP
J Gastrointest Cancer; 2018 Dec; 49(4):442-454. PubMed ID: 28691139
[TBL] [Abstract][Full Text] [Related]
13. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus.
Nguyen DM; Richardson P; El-Serag HB
Gastroenterology; 2010 Jun; 138(7):2260-6. PubMed ID: 20188100
[TBL] [Abstract][Full Text] [Related]
14. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans.
Tan MC; El-Serag HB; Yu X; Thrift AP
Aliment Pharmacol Ther; 2018 Aug; 48(4):469-477. PubMed ID: 29956826
[TBL] [Abstract][Full Text] [Related]
15. Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
Thrift AP
Curr Opin Gastroenterol; 2016 Jul; 32(4):319-24. PubMed ID: 27276368
[TBL] [Abstract][Full Text] [Related]
16. Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis.
Choi SE; Perzan KE; Tramontano AC; Kong CY; Hur C
Cancer Prev Res (Phila); 2014 Mar; 7(3):341-50. PubMed ID: 24380852
[TBL] [Abstract][Full Text] [Related]
17. The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett's oesophagus.
Thrift AP; Pandeya N; Smith KJ; Green AC; Webb PM; Whiteman DC
Aliment Pharmacol Ther; 2011 Nov; 34(10):1235-44. PubMed ID: 21967506
[TBL] [Abstract][Full Text] [Related]
18. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence.
Anderson LA; Johnston BT; Watson RG; Murphy SJ; Ferguson HR; Comber H; McGuigan J; Reynolds JV; Murray LJ
Cancer Res; 2006 May; 66(9):4975-82. PubMed ID: 16651456
[TBL] [Abstract][Full Text] [Related]
19. Nonsteroidal anti-inflammatory drugs and the risk of Barrett's esophagus.
Khalaf N; Nguyen T; Ramsey D; El-Serag HB
Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1832-9.e6. PubMed ID: 24793026
[TBL] [Abstract][Full Text] [Related]
20. Ghrelin and Leptin Have a Complex Relationship with Risk of Barrett's Esophagus.
Thomas SJ; Almers L; Schneider J; Graham JE; Havel PJ; Corley DA
Dig Dis Sci; 2016 Jan; 61(1):70-9. PubMed ID: 26396004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
